- Home
- VRCA vs NRSN Comparison
VRCA vs NRSN Comparison
Compare VRCA & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRCA
- NRSN
- Stock Information
- Founded
- VRCA 2013
- NRSN 2017
- Country
- VRCA United States
- NRSN Israel
- Employees
- VRCA N/A
- NRSN N/A
- Industry
- VRCA Biotechnology: Pharmaceutical Preparations
- NRSN Biotechnology: Pharmaceutical Preparations
- Sector
- VRCA Health Care
- NRSN Health Care
- Exchange
- VRCA Nasdaq
- NRSN Nasdaq
- Market Cap
- VRCA 32.7M
- NRSN 29.8M
- IPO Year
- VRCA 2018
- NRSN 2021
- Fundamental
- Price
- VRCA $4.54
- NRSN $1.12
- Analyst Decision
- VRCA Hold
- NRSN Buy
- Analyst Count
- VRCA 2
- NRSN 2
- Target Price
- VRCA N/A
- NRSN $14.00
- AVG Volume (30 Days)
- VRCA 93.9K
- NRSN 289.7K
- Earning Date
- VRCA 11-14-2025
- NRSN 12-17-2025
- Dividend Yield
- VRCA N/A
- NRSN N/A
- EPS Growth
- VRCA N/A
- NRSN N/A
- EPS
- VRCA N/A
- NRSN N/A
- Revenue
- VRCA $30,829,000.00
- NRSN N/A
- Revenue This Year
- VRCA $332.45
- NRSN N/A
- Revenue Next Year
- VRCA $12.85
- NRSN N/A
- P/E Ratio
- VRCA N/A
- NRSN N/A
- Revenue Growth
- VRCA 234.73
- NRSN N/A
- 52 Week Low
- VRCA $3.28
- NRSN $0.80
- 52 Week High
- VRCA $13.60
- NRSN $2.60
- Technical
- Relative Strength Index (RSI)
- VRCA 61.74
- NRSN 52.19
- Support Level
- VRCA $3.64
- NRSN $0.89
- Resistance Level
- VRCA $4.02
- NRSN $0.97
- Average True Range (ATR)
- VRCA 0.31
- NRSN 0.10
- MACD
- VRCA 0.10
- NRSN 0.02
- Stochastic Oscillator
- VRCA 92.28
- NRSN 57.70
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.